141 related articles for article (PubMed ID: 15102659)
1. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer.
Pisters LL; Pettaway CA; Troncoso P; McDonnell TJ; Stephens LC; Wood CG; Do KA; Brisbay SM; Wang X; Hossan EA; Evans RB; Soto C; Jacobson MG; Parker K; Merritt JA; Steiner MS; Logothetis CJ
Clin Cancer Res; 2004 Apr; 10(8):2587-93. PubMed ID: 15102659
[TBL] [Abstract][Full Text] [Related]
2. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
3. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
Swisher SG; Roth JA; Komaki R; Gu J; Lee JJ; Hicks M; Ro JY; Hong WK; Merritt JA; Ahrar K; Atkinson NE; Correa AM; Dolormente M; Dreiling L; El-Naggar AK; Fossella F; Francisco R; Glisson B; Grammer S; Herbst R; Huaringa A; Kemp B; Khuri FR; Kurie JM; Liao Z; McDonnell TJ; Morice R; Morello F; Munden R; Papadimitrakopoulou V; Pisters KM; Putnam JB; Sarabia AJ; Shelton T; Stevens C; Shin DM; Smythe WR; Vaporciyan AA; Walsh GL; Yin M
Clin Cancer Res; 2003 Jan; 9(1):93-101. PubMed ID: 12538456
[TBL] [Abstract][Full Text] [Related]
4. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
5. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy.
Sonpavde G; Thompson TC; Jain RK; Ayala GE; Kurosaka S; Edamura K; Tabata K; Ren C; Goltsov AA; Mims MP; Hayes TG; Ittmann MM; Wheeler TM; Gee A; Miles BJ; Kadmon D
Clin Cancer Res; 2011 Nov; 17(22):7174-82. PubMed ID: 21933889
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.
Tong AW; Nemunaitis J; Su D; Zhang Y; Cunningham C; Senzer N; Netto G; Rich D; Mhashilkar A; Parker K; Coffee K; Ramesh R; Ekmekcioglu S; Grimm EA; van Wart Hood J; Merritt J; Chada S
Mol Ther; 2005 Jan; 11(1):160-72. PubMed ID: 15585417
[TBL] [Abstract][Full Text] [Related]
7. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation.
Colletier PJ; Ashoori F; Cowen D; Meyn RE; Tofilon P; Meistrich ME; Pollack A
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1507-12. PubMed ID: 11121656
[TBL] [Abstract][Full Text] [Related]
8. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.
Swisher SG; Roth JA; Nemunaitis J; Lawrence DD; Kemp BL; Carrasco CH; Connors DG; El-Naggar AK; Fossella F; Glisson BS; Hong WK; Khuri FR; Kurie JM; Lee JJ; Lee JS; Mack M; Merritt JA; Nguyen DM; Nesbitt JC; Perez-Soler R; Pisters KM; Putnam JB; Richli WR; Savin M; Schrump DS; Shin DM; Shulkin A; Walsh GL; Wait J; Weill D; Waugh MK
J Natl Cancer Inst; 1999 May; 91(9):763-71. PubMed ID: 10328106
[TBL] [Abstract][Full Text] [Related]
10. Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy.
Tamura RE; da Silva Soares RB; Costanzi-Strauss E; Strauss BE
Cancer Biol Ther; 2016 Dec; 17(12):1221-1230. PubMed ID: 27646031
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
Zeng L; Rowland RG; Lele SM; Kyprianou N
Hum Pathol; 2004 Mar; 35(3):290-7. PubMed ID: 15017584
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies.
Merritt JA; Roth JA; Logothetis CJ
Semin Oncol; 2001 Oct; 28(5 Suppl 16):105-14. PubMed ID: 11706402
[TBL] [Abstract][Full Text] [Related]
13. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone.
Erbersdobler A; Fritz H; Schnöger S; Graefen M; Hammerer P; Huland H; Henke RP
Eur Urol; 2002 Jan; 41(1):40-6. PubMed ID: 11999464
[TBL] [Abstract][Full Text] [Related]
14. Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33(ING1) in T.Tn human esophageal carcinoma cells.
Shimada H; Liu TL; Ochiai T; Shimizu T; Haupt Y; Hamada H; Abe T; Oka M; Takiguchi M; Hiwasa T
Oncogene; 2002 Feb; 21(8):1208-16. PubMed ID: 11850840
[TBL] [Abstract][Full Text] [Related]
15. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.
Eastham JA; Grafton W; Martin CM; Williams BJ
J Urol; 2000 Sep; 164(3 Pt 1):814-9. PubMed ID: 10953161
[TBL] [Abstract][Full Text] [Related]
16. Induction of Oxidants Distinguishes Susceptibility of Prostate Carcinoma Cell Lines to p53 Gene Transfer Mediated by an Improved Adenoviral Vector.
Tamura RE; Hunger A; Fernandes DC; Laurindo FR; Costanzi-Strauss E; Strauss BE
Hum Gene Ther; 2017 Aug; 28(8):639-653. PubMed ID: 28181816
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma.
Shimada H; Matsubara H; Shiratori T; Shimizu T; Miyazaki S; Okazumi S; Nabeya Y; Shuto K; Hayashi H; Tanizawa T; Nakatani Y; Nakasa H; Kitada M; Ochiai T
Cancer Sci; 2006 Jun; 97(6):554-61. PubMed ID: 16734736
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments].
Bouvet M; Bold RJ; Lee J; Evans DB; Abbruzzese JL; Chiao PJ; McConkey DJ; Chandra J; Chada S; Fang B; Roth JA
Ann Surg Oncol; 1998 Dec; 5(8):681-8. PubMed ID: 9869513
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity.
Sah NK; Munshi A; Nishikawa T; Mukhopadhyay T; Roth JA; Meyn RE
Mol Cancer Ther; 2003 Nov; 2(11):1223-31. PubMed ID: 14617796
[TBL] [Abstract][Full Text] [Related]
20. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
